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neous ICD. Complications included lead dislodgement
requiring repositioning in four patients.
Conclusions: The subcutaneous ICD system tested in this
study accurately senses and terminates VT/VF in approxi-
mately 98% of patients.
Perspective: Elimination of radiation exposure and need for
vascular access make the subcutaneous ICD an attractive
option. However, it is not capable of long-term pacing,
antitachycardia pacing, or detection of VT <170 bpm.
Further evaluation is needed to determine its clinical relia-
bility and utility.   
Summary written by: Fred Morady, MD
Relationship of Functional Mitral Regurgitation to
New-Onset Atrial Fibrillation in Acute Myocardial
Infarction
Bahouth F, Mutlak D, Furman M, et al.
Heart 2010;96:683–688.
Study Question: Does functional mitral regurgitation (FMR)
occurring after acute myocardial infarction (AMI) promote
atrial fibrillation (AF) by producing left atrial volume 
overload?
Methods: A total of 1,920 patients admitted with AMI were
studied; patients with known AF were excluded. FMR using
echocardiography was classified into three groups: none,
mild FMR, and moderate or severe FMR. The relationship
between FMR and AF occurring at any time during the
hospital course was examined.
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Arrhythmias
An Entirely Subcutaneous Implantable
Cardioverter-Defibrillator
Bardy GH, Smith WM, Hood MA, et al.
N Engl J Med 2010;May 12:[Epub ahead of print].
Study Question: How effectively does a subcutaneous
implantable cardioverter-defibrillator (ICD) system detect
and terminate ventricular tachycardia (VT) and ventricular
fibrillation (VF)?
Methods: This study describes results of two short-term trials
of a subcutaneous electrode system and two long-term trials
of the subcutaneous ICD system. In the short-term trials,
the best electrode configuration was identified in 78 patients
and then compared to a transvenous ICD system in 49
patients. In the long-term trials, 61 patients underwent
implantation of the subcutaneous ICD, which consisted of a
pulse generator implanted in the anterior axillary region and
a parasternal 8-cm tripolar electrode. The pulse generator
delivered 80-J shocks, had a rate cut-off of 170 bpm, and
was able to pace for ≤30 seconds after a shock if there was a
>3.5 second pause after a shock.
Results: The mean defibrillation threshold was 11.1 J with the
transvenous ICD and 31.1 J with the subcutaneous ICD.
Among the subcutaneous ICD patients, two consecutive
episodes of induced VF were successfully sensed and termi-
nated by 65-J shocks in all but one patient. During a mean 10
months of follow-up, 12 episodes of VT in three patients
were detected and successfully terminated by the subcuta-
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ence in the mean time to hospitalization for CHF.
Conclusions: The reduction in time to first cardiovascular
hospitalization or death associated with use of dronedarone
was not attenuated by presence of class II-III CHF.
Perspective: Dronedarone is contraindicated in patients with
NYHA class IV CHF or a recent episode of class II-III
CHF because mortality was increased by dronedarone when
administered to patients with unstable CHF in the
ANDROMEDA trial. Results of the present study suggest
that dronedarone is safe in patients with ‘stable’ class II-III
CHF, defined as no exacerbation of CHF within the prior 
3 months.  
Summary written by: Fred Morady, MD
Cardiovascular Surgery
Transapical Transcatheter Aortic Valve
Implantation: Follow-up to 3 Years
Ye J, Cheung A, Lichtenstein SV, et al.
J Thorac Cardiovasc Surg 2010;139:1107–1113.
Study Question: What are the clinical and echocardiographic
outcomes of transapical aortic valve implantation?
Methods: Between October 2005 and February 2009, 71
patients (44 female) underwent transcatheter transapical aor-
tic valve implantation with either 23- or 26-mm Edwards
Lifesciences transcatheter bioprostheses. All patients with
symptomatic aortic stenosis were declined for both conven-
tional aortic valve replacement and transfemoral aortic valve
implantation. Clinical and echocardiographic follow-up was
performed before discharge, at 1 and 6 months, and then
yearly. Mean follow-up was 12.9 ± 11.5 months, with a total
follow-up of 917.3 patient-months.
Results: Mean age was 80.0 ± 8.1 years; predicted operative
mortality was 34.5% ± 20.4% by logistic EuroSCORE and
12.1% ± 7.7% by the Society of Thoracic Surgeons Risk
Calculator. Valves were successfully implanted in all patients.
Twelve patients (16.9%) died within 30 days, and 10 patients
died subsequently. Overall survival at 24 and 36 months was
66.3% ± 6.4% and 58.0% ± 9.5%, respectively. Among 59
patients who survived at least 30 days, 24- and 36-month sur-
vivals were 79.8% ± 6.4% and 69.8% ± 10.9%, respectively.
New York Heart Association functional class improved signif-
icantly from preoperative 3.3 ± 0.8 to 1.8 ± 0.8 at 24 months.
The aortic valve area and mean gradient remained stable at 24
months (1.6 ± 0.3 cm2 and 10.3 ± 5.9 mm Hg, respectively).
Conclusions: Transapical transcatheter aortic valve implanta-
tion provides sustained clinical and hemodynamic benefits
for up to 36 months in selected high-risk patients with
symptomatic severe aortic stenosis.
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Results: Mild FMR was present in 744 patients (38.8%) and
moderate or severe FMR in 150 patients (7.8%). AF devel-
oped in 51, 83, and 28 patients with no FMR, mild FMR,
and moderate or severe FMR, respectively (p < 0.001). In
multivariable logistic regression, both mild (p = 0.02) and
moderate or severe FMR (p = 0.007) were independent pre-
dictors of AF. There was a significant interaction between the
left ventricular ejection fraction and FMR (p = 0.003); mild
FMR was predictive of AF only in patients with a reduced
(<45%) ejection fraction. After discharge, new AF complicat-
ing AMI was strongly associated with subsequent readmission
for heart failure (hazard ratio, 3.7). Independent predictors of
mortality were renal insufficiency, Killip class, ejection frac-
tion, and severity of FMR.
Conclusions: There is a graded independent association
between the severity of FMR and the new onset of AF in
patients with AMI.
Perspective: It makes sense that increased left atrial volume
and pressure associated with FMR predispose to the develop-
ment of AF among patients presenting with AMI. Although
mortality after hospital discharge was significantly worse
among patients with AF, AF was not an independent predic-
tor of mortality in this study. It seems unlikely that
restoration of sinus rhythm would improve prognosis. Rather,
new AF during admission for AMI should be considered a
marker for other conditions that define a poor prognosis.  
Summary written by: David S. Bach, MD
Dronedarone in Patients With Congestive Heart
Failure: Insights From ATHENA
Hohnloser SH, Crijns HJ, van Eickels M, et al., on behalf of the
ATHENA Investigators.
Eur Heart J 2010;April 30:[Epub ahead of print].
Study Question: Does dronedarone increase mortality or mor-
bidity in patients with atrial fibrillation (AF) and congestive
heart failure (CHF)?
Methods: This was a post-hoc analysis of ATHENA, a ran-
domized clinical trial that compared dronedarone to placebo
in 4,628 patients with AF. The 1° endpoint was a composite
of time to first cardiovascular hospitalization or death.
Results: A total of 209 patients had New York Heart
Association (NYHA) functional class II or III CHF and a left
ventricular ejection fraction (LVEF) ≤40%. Dronedarone
decreased the 1° endpoint by 22% in patients with CHF and
24% without CHF. Adverse events in patients with CHF who
received dronedarone included bradycardia (3.2%), QT-pro-
longation (4.2%), and creatinine increase (10.5%); prevalence
did not differ significantly between patients with and without
CHF. NYHA class IV CHF occurred during follow-up in 54
placebo patients and 42 dronedarone patients, with no differ-
ulation are females, those who are highly symptomatic, and
those with a small aortic prosthesis.
Perspective: Current American Heart Association/American
College of Cardiology guidelines recommend anticoagulation
and antiplatelet therapy during the first 90 postoperative days
after bioprosthetic AVR; however, there is wide variability in
practice. This study suggests that using warfarin after biopros-
thetic AVR might be reserved for patients at increased risk of
thromboembolism.  
Summary written by: David S. Bach, MD
Congenital Heart Disease
Conventional and Chest-Compression-Only
Cardiopulmonary Resuscitation by Bystanders for
Children Who Have Out-of-Hospital Cardiac
Arrests: A Prospective, Nationwide, Population-
Based Cohort Study
Kitamura T, Iwami T, Kawamura T, et al., on behalf of the
Implementation Working Group for All-Japan Utstein Registry of the
Fire and Disaster Management Agency.
Lancet 2010;375:1347–1354.
Study Question: What is the optimal type of cardiopulmonary
resuscitation (CPR) for pediatric patients with out-of-hospi-
tal cardiac arrest (OHCA)?
Methods: The data in this study were obtained from a nation-
wide registry of OHCAs in Japan. Children ages 17 years or
younger were included. The 1° outcome was favorable neuro-
logical outcome at 1 month of follow-up.
Results: Data from 5,170 children with OHCA were analyzed.
The OHCA was from a noncardiac cause in 71% of patients.
One-month survival with favorable neurological outcome was
3.2%. Bystanders witnessed 27% of the OHCAs. When there
was a noncardiac cause, the 1° outcome was significantly more
frequent after bystander CPR (5.1%) than with no bystander
CPR (1.5%) and after conventional CPR (7.2%) than after
compression-only CPR (1.6%). When there was a cardiac
cause of OHCA, the incidence of the 1° outcome was signifi-
cantly higher with bystander CPR (9.5%) than without
(4.1%), but did not differ significantly after conventional
(9.9%) versus compression-only CPR (8.9%).
Conclusions: Rescue breaths provide incremental value com-
pared to compression-only CPR in children with OHCA,
but only when the cardiac arrest results from a noncardiac
etiology.
Perspective: Observational studies in adults have indicated
that compression-only CPR yields similar or better out-
comes than does conventional CPR in adults with OHCA,
and the American Heart Association now recommends
Perspective: Physicians in Europe and Canada have been using
approved devices for transcatheter aortic valve replacement
(TAVI) for several years.  These devices offer a form of ther-
apy for patients with a mortal disease and no other realistic
option. These data suggest that the transapical approach, in
the right hands and after a significant initial learning curve,
appears to be a viable option for what may be the highest risk
patients––inoperable patients with vascular access inadequate
for retrograde TAVI.  
Summary written by: David S. Bach, MD
Is Early Antithrombotic Therapy Necessary in
Patients With Bioprosthetic Aortic Valves in
Normal Sinus Rhythm?
ElBardissi AW, DiBardino DJ, Chen FY, Yamashita MH, Cohn LH.
J Thorac Cardiovasc Surg 2010;139:1137–1145.
Study Question: Is early antithrombotic therapy necessary in
patients undergoing isolated bioprosthetic aortic valve replace-
ment (AVR), who are discharged in normal sinus rhythm?
Methods: From December 2001 to October 2008, 1,131
patients underwent isolated bioprosthetic AVR at one aca-
demic center. After exclusion of patients who underwent
concomitant operations (n = 138, 12%), were anticoagulated
preoperatively (n = 4, 0.4%), and experienced postoperative
refractory atrial fibrillation requiring anticoagulation at dis-
charge (n = 128, 11%), the study cohort comprised 861
patients. Patients were followed for 90 days postoperatively
for the occurrence of thromboembolism.
Results: Of 861 patients, 133 were anticoagulated with war-
farin postoperatively (AC+) and 728 were not (AC–). Patients
who received postoperative anticoagulation were older; had a
higher incidence of hypertension, cerebrovascular accident,
and pulmonary vascular disease; and were more symptomatic
at presentation. The 90-day risk of thromboembolism after
surgery was 5% in those who were anticoagulated and 5% in
those who were not (p = 0.67). Independent predictors of
thromboembolism were increasing age, female gender, short
stature, smoking status, New York Heart Association class
III/IV, and a 19-mm bioprosthetic aortic valve prosthesis.
Evaluation of each predictor with postoperative acetylsalicylic
acid use (ASA+) and AC+ interaction terms revealed that
female patients and patients with a 19-mm bioprosthetic aor-
tic valve had a reduction in thromboembolism when
administered ASA or warfarin. Patients in class III/IV also
had a reduction of thromboembolism when treated with war-
farin and with ASA.
Conclusions: Early anticoagulation after isolated bioprosthetic
AVR in patients in normal sinus rhythm does not reduce
the risk of thromboembolism, except in high-risk groups. In
this study, the only patients who may benefit from anticoag-
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compression-only CPR for OHCA of presumed cardiac ori-
gin. In children, OHCA is more often noncardiac in
etiology. Therefore, unless there is a sudden collapse consis-
tent with a cardiac-based OHCA, conventional CPR with
rescue breaths is indicated.  
Summary written by: Fred Morady, MD
General Cardiology
The Effects of Growth Hormone on Body
Composition and Physical Performance in
Recreational Athletes: A Randomized Trial 
Meinhardt U, Nelson AE, Hansen JL, et al.
Ann Intern Med 2010;152:568–577.
Study Question: What are the effects of growth hormone
alone, or in combination with testosterone, on body compo-
sition and measures of athletic performance?
Methods: In a randomized, placebo-controlled, blinded study
sponsored by the World Anti-Doping Agency, 96 recreation-
ally trained athletes (63 men and 33 women, mean age 27.9 ±
5.7 years) underwent treatment for 8 weeks followed by a 6-
week washout period. Men were randomly assigned to receive
placebo, growth hormone (2 mg/d subcutaneously), testos-
terone (250 mg/wk intramuscularly), or combined growth
hormone and testosterone. Women were randomly assigned
to receive either placebo or growth hormone (2 mg/d). Body
composition and physical performance variables (endurance,
strength, power, and sprint capacity) were assessed.
Results: Body cell mass was correlated with all measures of
performance at baseline. In men, growth hormone co-
administered with testosterone significantly reduced fat
mass, increased lean body mass through an increase in extra-
cellular water, and increased body cell mass. Growth
hormone significantly increased sprint capacity by 0.71 kJ in
men and women combined, and by 1.7 kJ when co-adminis-
tered with testosterone in men; other performance measures
did not significantly change. The increase in sprint capacity
was not maintained 6 weeks after discontinuation of the
drug. The authors note that growth hormone dosage may
have been lower than that used covertly by competitive ath-
letes; the athletic significance of the observed improvements
in sprint capacity is unclear; and the study was too small to
draw conclusions about safety.
Conclusions: Growth hormone supplementation influenced
body composition and increased sprint capacity when
administered alone and in combination with testosterone.
Perspective: Growth hormone is widely abused by athletes,
frequently in combination with androgenic steroids.
Although there could be surprises in the world, this study
serves to confirm that people do things for a reason. Growth
hormone makes you faster.  
Summary written by: David S. Bach, MD
Time to Treatment With Intravenous Alteplase and
Outcome in Stroke: An Updated Pooled Analysis of
ECASS, ATLANTIS, NINDS, and EPITHET Trials
Lees KR, Bluhmki E, von Kummer R, et al., on behalf of the ECASS,
ATLANTIS, NINDS, and EPITHET rt-Pa Study Group Investigators.
Lancet 2010;375:1695–1703.
Study Question: What is the contemporary effect of time to
treatment with intravenous rt-PA (alteplase) on therapeutic
benefit and clinical risk?
Methods: The authors added data from ECASS III (821
patients) and EPITHET (100 patients) trials to a pool of
common elements from six other trials of alteplase for acute
stroke (2,775 patients). Multivariate logistic regression was
used to assess the relation of stroke onset to start of treatment
(OTT) with treatment on favorable 3-month outcome
(defined as modified Rankin score 0-1), mortality, and occur-
rence and outcome of clinically relevant parenchymal
hemorrhage. All patients with confirmed OTT within 360
minutes were included.
Results: Treatment was started within 360 minutes of stroke
onset in 3,670 patients randomly allocated to alteplase (n =
1,850) or to placebo (n = 1,820). Odds of a favorable 3-month
outcome increased as OTT decreased (p = 0.0269) and no
benefit of alteplase treatment was seen after around 270 min-
utes. Adjusted odds of a favorable 3-month outcome were
2.55 for 0-90 minutes, 1.64 for 91-180 minutes, 1.34 for 181-
270 minutes, and 1.22 for 271-360 minutes in favor of the
alteplase group. Large parenchymal hemorrhage was seen in
96 of 1,850 patients assigned to alteplase and 18 of 1,820 con-
trols, with no clear relation to OTT (p = 0.4140). Adjusted
odds of mortality increased with OTT (p = 0.0444) and were
0.78 for 0-90 minutes, 1.13 for 91-180 minutes, 1.22 for 181-
270 minutes, and 1.49 for 271-360 minutes.
Conclusions: Patients with ischemic stroke selected by clinical
symptoms and CT benefit from intravenous alteplase when
treated up to 4.5 hours.
Perspective: This analysis suggests that serious hemorrhage
rates are independent of stroke onset to start of treatment
(OTT), but unfavorable outcomes including mortality
increase with OTT longer than 4.5 hours. These findings
should spur a renewed commitment by emergency physicians,
neurologists, and policy makers to target very early interven-
tion with a proposed door-to-needle time of <60 minutes in
the great majority of patients.  
Summary written by: Debabrata Mukherjee, MD
importance of closely examining preoperative laboratory and
cardiopulmonary hemodynamics in order to gauge RVF risk.
It also identifies a weakness in predicting delayed RVF in
LVAD patients.  
Summary written by: Jennifer Cowger, MD
Peripartum Cardiomyopathy as a Part of Familial
Dilated Cardiomyopathy
van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al.
Circulation 2010;121:2169–2175.
Study Question: What is the role of genetic factors in the patho-
genesis of peripartum cardiomyopathy (PPCM)?
Methods: The investigators reviewed their database of 90
dilated cardiomyopathy (DCM) families, focusing on PPCM
patients. In a reverse approach, they reviewed 10 PPCM
patients seen in their clinic since the early 1990s and per-
formed cardiological screening of the first-degree relatives of
three PPCM patients who did not show a full recovery.
Finally, they analyzed the genes known to be most commonly
involved in DCM in the PPCM patients.
Results: The investigators identified a substantial number (5 of
90) of DCM families with PPCM patients. Cardiological
screening of first-degree relatives of three PPCM patients who
did not show full recovery revealed undiagnosed DCM in all
three families. Genetic analyses revealed a mutation (c.149A>G,
p.Gln50Arg) in the gene encoding cardiac troponin C
(TNNC1) segregating with disease in a DCM family with a
member with PPCM, supporting the genetic nature of disease.
Conclusions: These findings strongly suggest that a subset of
PPCM is an initial manifestation of familial DCM.
Perspective: Additional research is needed to confirm these
study findings and to better understand the interaction
between oxidative stress associated with the peripartum /
postpartum period and genetic factors. Based on the study, it
may be reasonable to do presymptomatic screening for covert
DCM in first-degree relatives of PPCM patients using non-
invasive techniques.  
Summary written by: Debabrata Mukherjee, MD
Relationship Between Early Physician Follow-up and
30-Day Readmission Among Medicare Beneficiaries
Hospitalized for Heart Failure 
Hernandez AF, Greinger MA, Fonarow GC, et al.
JAMA 2010;303:1716–1722. 
Study Question: What is the association between outpatient fol-
low-up within 7 days after discharge from a heart failure (HF)
hospitalization and readmission within 30 days?
Heart Failure/Transplant
Right Ventricular Failure in Patients With the
HeartMate II Continuous-Flow Left Ventricular
Assist Device: Incidence, Risk Factors, and Effects
on Outcomes 
Kormos RL, Teuteberg JJ, Pagani FD, et al., on behalf of the
HeartMate II Clinical Investigators.
J Thorac Cardiovasc Surg 2010;139:1316–1324. 
Study Question: What is the cumulative incidence of postoper-
ative right ventricular failure (RVF) development following
HeartMate II left ventricular assist device (LVAD) place-
ment, and what are preoperative risks for RVF?
Methods: A retrospective analysis of clinical, laboratory, and
cardiopulmonary hemodynamic data from 484 patients
enrolled into the HeartMate II bridge-to-transplant trial was
conducted. RVF had three definitions: RVAD requirement,
need for intravenous inotropes >14 days after LVAD place-
ment, or inotrope requirement beginning >14 days after
LVAD. Preoperative variables in those with and without post-
operative RVF were compared to identify correlates of early
RVF development.
Results: Ninety-eight (20%) subjects developed postoperative
RVF: 30 required an RVAD, 35 required inotrope support
for >14 days immediately after implant, and 33 required ini-
tiation of delayed inotrope support. The 180-day survival for
those with and without early RVF was 66 ± 0.06% and 85 ±
0.02%, respectively, and individuals with RVF had longer
bypass times, more perioperative bleeding, and longer hospi-
tal stays. Several preoperative univariable correlates (central
venous pressure [CVP], CVP/pulmonary capillary wedge
pressure [WP] ratio, RVSWi, ventilator support, blood urea
nitrogen [BUN], AST, Right Ventricular Failure Risk
Score) of “early RVF” development were identified, but only
an elevated preoperative AST was associated with late RVF
onset. Multivariable correlates of “early RVF” included a
preoperative CVP/WP ratio >0.63, preoperative ventilator
support, and BUN >39 mg/dl.
Conclusions: RVF continues to be a problem following continu-
ous-flow LVAD support. Preoperative optimization of RV
function or planned biventricular support may be beneficial.
Perspective: While the morbidity and mortality associated
with post-LVAD RVF is well known, this is the first study
examining RVF in a large cohort undergoing implant of a
commonly employed, contemporary, continuous-flow
device. Preoperative univariable predictors may have been
correlated, variable dichotomization was potentially biased,
and power was limited to perform detailed multivariable
analyses required to identify truly independent RVF risk
predictors. Regardless, this study again highlights the
JACC, Vol 56, No. 2, 2010
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Methods: The study cohort consisted of 30,136 patients from
225 hospitals. The study was an observational analysis of
patients ages ≥65 years with HF and discharged to home
from hospitals participating in the HF quality improvement
program from January 1, 2003, through December 31, 2006.
The main outcome measure was all-cause readmission within
30 days after discharge.
Results: Median length of stay was 4 days and 21.3% of
patients were readmitted within 30 days. At the hospital level,
the median percentage of patients who had early follow-up
after discharge from the index hospitalization was 38.3%.
Compared with patients whose index admission was in a hos-
pital in the lowest quartile of early follow-up, the rates of
30-day readmission were 20.5% among patients in the second
quartile, 20.5% among patients in the third quartile, and
20.9% among patients in the fourth quartile.
Conclusions: Patients who are discharged from hospitals that
have higher early follow-up rates have a lower risk of 30-day
readmission.
Perspective: From Ragavendra R. Baliga, MBBS: This important
study confirms what HF physicians have always known
about the importance of timely follow-up of patients after
discharge from an index HF hospitalization. These data are
particularly helpful to hospitals trying to put together a
strategy to reduce re-admission rates for hospitalizations. It
would be interesting to know whether early and regular fol-
low-up of HF patients eventually also results in improved
long-term survival.  
Expert Commentary From Alfred A. Bove, MD: Until now, early fol-
low-up for HF patients after discharge had face validity only.
This study confirms the importance of establishing coordi-
nated systems of care in which patients are evaluated early
after discharge. The American College of Cardiology's
national quality improvement initiative, Hospital to Home
(H2H), identifies early follow-up as one of three core con-
cepts for reducing hospital readmissions. Discharged patients
should have a follow-up visit scheduled within 1 week of dis-
charge, as well as the means of getting to that appointment.
Summary written by: Ragavendra R. Baliga, MBBS
Interventional Cardiology
Everolimus-Eluting Versus Paclitaxel-Eluting
Stents in Coronary Artery Disease
Stone GW, Rizvi A, Newman W, et al., on behalf of the SPIRIT IV
Investigators.
N Engl J Med 2010;362:1663–1674.
Study Question: What is the comparative efficacy of
everolimus-eluting versus paclitaxel-eluting stents?
Methods: The SPIRIT IV investigators randomly assigned
3,687 patients at 66 US sites to receive everolimus- or pacli-
taxel-eluting stents without routine follow-up angiography.
The primary endpoint was a 1-year composter rate of target
lesion failure (defined as cardiac death, target vessel myocardial
infarction, or ischemia-driven target lesion revascularization).
Results: Everolimus-eluting stents were superior to paclitaxel-
eluting stents with respect to the primary endpoint of target
lesion failure (4.2% vs. 6.8%). Everolimus-eluting stents were
also superior with respect to the major secondary endpoint of
the 1-year rate of ischemia-driven target lesion revasculariza-
tion (p = 0.001) and were noninferior with respect to the major
secondary endpoint of the 1-year composite rate of cardiac
death target lesion myocardial infarction (p < 0.001 for nonin-
feriority, p = 0.09 for superiority). The 1-year rates of
myocardial infarction and stent thrombosis were also lower
with everolimus-eluting than with paclitaxel-eluting stents
(1.9% vs. 3.1%). Target lesion failure was consistently reduced
with everolimus-eluting compared with paclitaxel-eluting
stents in 12 prespecified subgroups, except in the subgroup of
patients with diabetes (6.4% vs. 6.9%).
Conclusions: Everolimus-eluting compared with paclitaxel-
eluting stents resulted in reduced rates of target vessel failure
at 1 year.
Perspective: The study suggests that with drug-eluting stents, it
is possible to achieve minimal late loss with improved clinical
efficacy, but without sacrificing safety or any increase in stent
thrombosis. The lack of superiority of everolimus-eluting
stents among diabetics calls for additional research on newer
drugs in this high-risk cohort. Additional studies comparing
everolimus-eluting with sirolimus- and zotarolimus-eluting
stents are also indicated to gauge comparative efficacy with
other drug-eluting stents.  
Summary written by: Debabrata Mukherjee, MD 
Antithrombotic Management of Atrial Fibrillation
Patients Presenting With Acute Coronary
Syndrome and/or Undergoing Coronary Stenting:
Executive Summary—A Consensus Document of
the European Society of Cardiology Working Group
on Thrombosis, Endorsed by EHRA and EAPCI
Lip GY, Huber K, Andreotti F, et al.
Eur Heart J 2010;May 6:[Epub ahead of print].
Perspective: The following are 10 points to remember from
this consensus document:
1: Approximately 70-80% of patients with atrial fibrillation
(AF) have an indication for oral anticoagulation therapy
(OAT). Coronary artery disease co-exists in 20-30% of these
patients. 
2: Patients with AF on OAT are often bridged with unfrac-
tionated heparin or low molecular weight heparin if they need
coronary angiography or percutaneous coronary intervention
(PCI). Use of bridging therapy is associated with increased
risk of access site complications in some studies.
3: In small series, complications in patients on OAT who
undergo angiography or PCI via the femoral route have
been low. However, the radial route should be preferred in
patients on OAT.
4: There is no need for additional heparin in patients who
undergo PCI while therapeutic on OAT (international nor-
malized ratio [INR] 2-3).   
5: Aspirin and clopidogrel should be administered prior to
PCI if performed in a patient on OAT.
6: Platelet glycoprotein IIb/IIIa inhibitors increase the risk of
bleeding in patients on OAT 3- to 13-fold and routine use of
these agents should be avoided in patients on OAT.  
7: Aspirin and warfarin do not provide sufficient protection
against risk of stent thrombosis. Patients undergoing stent-
based PCI should be treated with triple therapy: aspirin,
clopidogrel, and warfarin. This combination is associated with
an increased risk of bleeding, and use of bare-metal stents
should be considered to limit the duration of triple therapy.
8: In patients who need long-term OAT, use of drug-eluting
stents should be restricted to patients at very high risk of
restenosis (long lesions, small vessels, diabetes). Alternative
therapies should be considered before implanting drug-eluting
stents in a patient who needs long-term OAT.   
9: In patients on triple therapy, closer monitoring of INR
targeted to 2.0-2.5 and use of proton pump inhibitors may
help reduce the risk of bleeding.
10: There are limited data on safety of cardiac surgery in
patients on OAT. Currently, these patients are bridged with
heparin prior to surgery. If emergent CABG is needed in a
patient on OAT, fresh frozen plasma and vitamin K may
reverse OAT and reduce the risk of bleeding.  
Summary written by: Hitinder S. Gurm, MBBS 
Noninvasive Cardiology
Effect of Early Cerebral Magnetic Resonance
Imaging on Clinical Decisions in Infective
Endocarditis: A Prospective Study
Duval X, Iung B, Klein I, et al., on behalf of the IMAGE (Resonance
Magnetic Imaging at the Acute Phase of Endocarditis) Study Group.
Ann Intern Med 2010;152:497–504.
Study Question: Does early cerebral magnetic resonance imaging
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(MRI) affect the diagnosis and management of infective
endocarditis in hospitalized adults?
Methods: In a single-center (tertiary care hospital in France)
prospective study performed between June 2005 and October
2008, cerebral MRI with angiography was performed in 130
patients hospitalized with infective endocarditis up to 7 days
after admission and before surgical intervention. Two
experts jointly established the endocarditis diagnostic classi-
fication (modified Duke criteria), and therapeutic plans just
before and after MRI.
Results: Endocarditis was initially classified as definite in 77
patients, possible in 50, and was excluded in 3. Acute neu-
rologic symptoms were present in 16 patients. Cerebral
lesions were detected on MRI in 106 patients, including
ischemic lesions in 68, micro-hemorrhages in 74, and silent
aneurysms in 10. Solely on the basis of MRI results and
excluding micro-hemorrhages, diagnostic classification of 17
of 53 cases of nondefinite endocarditis was changed to
either definite (14 patients) or possible (3 patients). MRI
results led to modification of endocarditis therapeutic plan
in 24 of 130 patients, including surgical plan modifications
for 18. Overall, early MRI led to modifications of diagnosis
or therapeutic plan in 36 patients.
Conclusions: Cerebral lesions were identified on MRI in
many patients with endocarditis, but no neurologic symp-
toms. The MRI findings affected both diagnostic
classifications and clinical management plans.
Perspective: The present study showed an increase in rate of
diagnosis of infective endocarditis, and altered medical
and/or surgical management in patients with evidence of
subclinical brain pathology. However, it is not known
whether the additional data actually should have altered
therapy, or in any way improved outcomes. If existing diag-
nostic criteria and therapeutic recommendations include the
presence or absence of clinically apparent embolic events, it
does not logically follow that management should be altered
by extrapolation to include subclinical events. Doing more
tests will result in the detection of more abnormalities; how-
ever, improved clinical outcomes should remain the relevant
endpoint.  
Summary written by: David S. Bach, MD
Diagnostic Accuracy and Clinical Utility of
Noninvasive Testing for Coronary Artery Disease
Weustink AC, Mollet NR, Neefjes LA, et al.
Ann Intern Med 2010;152:630–639.
Study Question: What is the relative accuracy and clinical util-
ity of stress testing and computed tomographic coronary
arteriography (CTCA) for identifying patients who require
invasive coronary angiography (ICA)?
Methods: This observational study was conducted in patients
referred for chest pain in a single academic center. In 2004 to
2006, 297 patients underwent stress testing with electrocardio-
gram (ECG) and nuclear imaging, CTCA, and ICA. In 2006
to 2008, all 220 patients underwent stress testing and CTCA.
The 141 patients with a normal stress ECG, imaging, and
CTCA were considered to have no coronary disease.
Diagnostic accuracy of stress testing and CTCA was compared
with ICA; pretest probabilities of disease by Duke clinical
score; and clinical utility of noninvasive testing, defined as a
pretest or post-test probability that suggests how to proceed
with testing (no further testing if ≤5%, proceed with ICA if
between 5% and 90%, and refer directly for ICA if ≥90%). 
Results: Mean age was 58.9 years, and 61% were men; chest
pain was typical angina in 43.1%, atypical angina in 21.5%,
and nonangina in 35%. Significant obstructive CAD on ICA
was present in 53%, nonsignificant in 11%, and no CAD in
35%. Stress testing was not as accurate as CTCA; CTCA
sensitivity approached 100%. In patients with a low (≤20%)
pretest probability of disease, negative stress test, or CTCA
results suggested no need for ICA. In patients with an inter-
mediate (20-80%) pretest probability, a positive CTCA
result suggested need to proceed with ICA, and a negative
result suggested no need for further testing. Physicians could
proceed directly with ICA in patients with a high (≥80%)
pretest probability.
Conclusions: CTCA seems most valuable in patients with inter-
mediate pretest probability of disease, because the test can
distinguish which of these patients need ICA. These findings
need to be confirmed before CTCA can be routinely recom-
mended for these patients.
Perspective: The study does little to add to the decision
process for ICA, but does add to the literature that CTCA
can be useful in evaluation of chest pain. If not for relatively
high radiation exposure (8-13 mSv), it would be the diag-
nostic tool of choice both for accuracy and ability to identify
plaque burden that is not hemodynamically significant.  
Summary written by: Melvyn Rubenfire, MD
Prevention/Vascular
Triglyceride-Mediated Pathways and Coronary
Disease: Collaborative Analysis of 101 Studies
Sarwar N, Sandhu MS, Ricketts SL, et al., on behalf of the
Triglyceride Coronary Disease Genetics Consortium and Emerging
Risk Factors Collaboration.
Lancet 2010;375:1634–1639.
Study Question: Are triglyceride-mediated pathways causally
relevant to coronary heart disease (CHD)?
Methods: The study assessed the –1131T>C (rs662799) pro-
moter polymorphism of the apolipoprotein A5 (APOA5) gene
in relation to triglyceride concentration, several other risk fac-
tors, and risk of CHD. The disease risk was assessed for
genetically-raised triglyceride concentration (20,842 patients
with CHD and 35,206 controls) with that recorded for
equivalent differences in circulating triglyceride concentra-
tion in prospective studies (302,430 participants with no
history of cardiovascular disease; 12,785 incident cases of
CHD during 2.79 million person-years at risk). The
authors also analyzed –1131T>C in 1,795 people without a
history of cardiovascular disease who had information about
lipoprotein concentration and diameter obtained by nuclear
magnetic resonance spectroscopy.
Results: The minor allele frequency of –1131T>C was 8%. 
–1131T>C was not significantly associated with several
nonlipid risk factors or low-density lipoprotein (LDL) cho-
lesterol; however, it was significantly but modestly
associated with lower high-density lipoprotein cholesterol
(HDL-C). By contrast, for every C allele inherited, mean
triglyceride concentration was 16.0% or 0.25 mmol/L,
higher. The odds ratio for CHD was 1.18 per C allele,
which was concordant with the hazard ratio of 1.10 per
16% higher triglyceride concentration recorded in prospec-
tive studies. –1131T>C was significantly associated with
higher very LDL (VLDL) particle concentration and
smaller HDL particle size, factors that could mediate the
effects of triglyceride.
Conclusions: These data are consistent with a causal associa-
tion between triglyceride-mediated pathways and CHD.
Perspective: The mechanisms considered for triglycerides
increasing risk for CHD and cardiovascular events are
thought to be the increase in VLDL triglyceride-rich rem-
nant particles, small highly atherogenic LDL particles, less
efficient small dense HDL particles, and prothrombosis.
The finding that a genetic determinant of triglyceride levels
appears to increase risk independent of other known risk
factors including diabetes further supports the rationale for
considering targeting triglycerides. Future drug trials should
consider the impact of the –1131T>C (rs662799) promoter
polymorphism of the APOA5 gene, which appears to impact
the effect of both statins and fibrates.  
Summary written by: Melvyn Rubenfire, MD
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